Dabigatran etexilate (DE), a direct thrombin inhibitor administered orally, reduces both free and clot-bound thrombin, which may be useful to elucidate the roles of PAR1 and ET1 in the pathogenesis of parkinsonism. The gene discussed is F2R; the disease is Parkinson disease.